Studying whether two nucleotide-yeast-based food supplements can help maintain cognitive function in adults

Study of the efficacy and tolerability of two food supplements based on yeast extract, RiboDIET® (obtained from Kluyveromyces fragilis) and RiboMIX SC (obtained from Saccharomyces cerevisiae), as dietary sources of nucleotides, for the maintenance of cognitive function: single-center, randomized, placebo-controlled, parallel-arm, double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99002302

Enrollment

Registered

2026-03-02

Start date

2025-06-11

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance of cognitive function in subjects diagnosed with Mild Cognitive Impairment (MCI). Mental and Behavioural Disorders

Interventions

A single-center, randomized, placebo-controlled, parallel-arm, double-blind clinical trial was conducted with a treatment period of 24 weeks (approximately 6 months). Participants consumed one capsule

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 60 and 85 years 2. Able to understand and sign the informed consent 3. Able to understand and comply with the requirements of the protocol 4. Negative HIV test 5. Score between 20 and 25 on the Montreal Cognitive Assessment (MoCA) 6. Total score of 14 on Instrumental Activities of Daily Living (IADL) plus Activities of Daily Living (ADL) 7. Geriatric Depression Scale (GDS) score between 0 and 5 8. Score between 0 and 4 on the Generalized Anxiety Disorder questionnaire (GAD-7) 9. Not taking and not having recently taken drugs, including antidiabetics and drugs acting on the nervous system such as antidepressants, anxiolytics or opiates 10. Not taking antibiotics or not having taken antibiotics in the last four weeks, or in the last six months depending on the intensity and duration of the antibiotic treatment

Exclusion criteria

Exclusion criteria: 1. With age under 60 or over 85 years 2. Individuals with Montreal Cognitive Assessment (MoCA) scores below 20 or above 26 3. Individuals who did not show a willingness to collaborate 4. Individuals who had difficulty travelling to the study site on time 5. Individuals considered unsuitable by the investigator due to other medical conditions that were incompatible with enrolment or required medication (for example: active systemic diseases, diabetes, neurological or psychiatric conditions, including cognitive disorders that made it impossible to complete questionnaires) 6. Individuals with HIV-acquired immunodeficiency 7. Individuals with severe visual or hearing impairments 8. Individuals with known allergies to any ingredients in the investigational products (active or placebo) 9. Individuals who abuse alcohol, drugs, nicotine, caffeine or theine 10. Individuals who were taking medication

Countries

Italy

Contacts

Public ContactAlessandra;Lorenza Francesca Baldi;De Lellis

;

alessandra.baldi.alimenti@gmail.com;lo.delellis2@gmail.com+39 (0)3483854114;+39 (0)3883810763

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026